273 related articles for article (PubMed ID: 20454608)
1. A novel role for Wnt/Ca2+ signaling in actin cytoskeleton remodeling and cell motility in prostate cancer.
Wang Q; Symes AJ; Kane CA; Freeman A; Nariculam J; Munson P; Thrasivoulou C; Masters JR; Ahmed A
PLoS One; 2010 May; 5(5):e10456. PubMed ID: 20454608
[TBL] [Abstract][Full Text] [Related]
2. Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase.
Yamamoto H; Oue N; Sato A; Hasegawa Y; Yamamoto H; Matsubara A; Yasui W; Kikuchi A
Oncogene; 2010 Apr; 29(14):2036-46. PubMed ID: 20101234
[TBL] [Abstract][Full Text] [Related]
3. Regulation of prostate cancer cell migration toward bone marrow stromal cell-conditioned medium by Wnt5a signaling.
Jin F; Qu X; Fan Q; Wang L; Tang T; Hao Y; Dai K
Mol Med Rep; 2013 Nov; 8(5):1486-92. PubMed ID: 24064566
[TBL] [Abstract][Full Text] [Related]
4. WNT5A antagonizes WNT/β-catenin signaling and is frequently silenced by promoter CpG methylation in esophageal squamous cell carcinoma.
Li J; Ying J; Fan Y; Wu L; Ying Y; Chan AT; Srivastava G; Tao Q
Cancer Biol Ther; 2010 Sep; 10(6):617-24. PubMed ID: 20603606
[TBL] [Abstract][Full Text] [Related]
5. Expression profile of WNT molecules in prostate cancer and its regulation by aminobisphosphonates.
Thiele S; Rauner M; Goettsch C; Rachner TD; Benad P; Fuessel S; Erdmann K; Hamann C; Baretton GB; Wirth MP; Jakob F; Hofbauer LC
J Cell Biochem; 2011 Jun; 112(6):1593-600. PubMed ID: 21344486
[TBL] [Abstract][Full Text] [Related]
6. Wnt5a induces endothelial inflammation via beta-catenin-independent signaling.
Kim J; Kim J; Kim DW; Ha Y; Ihm MH; Kim H; Song K; Lee I
J Immunol; 2010 Jul; 185(2):1274-82. PubMed ID: 20554957
[TBL] [Abstract][Full Text] [Related]
7. Wingless-type mammary tumor virus integration site family, member 5A (Wnt5a) regulates human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein 120 (gp120)-induced expression of pro-inflammatory cytokines via the Ca2+/calmodulin-dependent protein kinase II (CaMKII) and c-Jun N-terminal kinase (JNK) signaling pathways.
Li B; Shi Y; Shu J; Gao J; Wu P; Tang SJ
J Biol Chem; 2013 May; 288(19):13610-9. PubMed ID: 23539626
[TBL] [Abstract][Full Text] [Related]
8. The TAK1-NLK mitogen-activated protein kinase cascade functions in the Wnt-5a/Ca(2+) pathway to antagonize Wnt/beta-catenin signaling.
Ishitani T; Kishida S; Hyodo-Miura J; Ueno N; Yasuda J; Waterman M; Shibuya H; Moon RT; Ninomiya-Tsuji J; Matsumoto K
Mol Cell Biol; 2003 Jan; 23(1):131-9. PubMed ID: 12482967
[TBL] [Abstract][Full Text] [Related]
9. WNT5A exhibits tumor-suppressive activity through antagonizing the Wnt/beta-catenin signaling, and is frequently methylated in colorectal cancer.
Ying J; Li H; Yu J; Ng KM; Poon FF; Wong SC; Chan AT; Sung JJ; Tao Q
Clin Cancer Res; 2008 Jan; 14(1):55-61. PubMed ID: 18172252
[TBL] [Abstract][Full Text] [Related]
10. Glypican-3 regulates migration, adhesion and actin cytoskeleton organization in mammary tumor cells through Wnt signaling modulation.
Stigliano I; Puricelli L; Filmus J; Sogayar MC; Bal de Kier Joffé E; Peters MG
Breast Cancer Res Treat; 2009 Mar; 114(2):251-62. PubMed ID: 18404367
[TBL] [Abstract][Full Text] [Related]
11. Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells.
Bolzoni M; Donofrio G; Storti P; Guasco D; Toscani D; Lazzaretti M; Bonomini S; Agnelli L; Capocefalo A; Dalla Palma B; Neri A; Nicolini F; Lisignoli G; Russo F; Colla S; Aversa F; Giuliani N
Leukemia; 2013 Feb; 27(2):451-63. PubMed ID: 22781592
[TBL] [Abstract][Full Text] [Related]
12. Wnt5a suppresses colon cancer by inhibiting cell proliferation and epithelial-mesenchymal transition.
Cheng R; Sun B; Liu Z; Zhao X; Qi L; Li Y; Gu Q
J Cell Physiol; 2014 Dec; 229(12):1908-17. PubMed ID: 24464650
[TBL] [Abstract][Full Text] [Related]
13. Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer.
Wang Q; Williamson M; Bott S; Brookman-Amissah N; Freeman A; Nariculam J; Hubank MJ; Ahmed A; Masters JR
Oncogene; 2007 Oct; 26(45):6560-5. PubMed ID: 17486081
[TBL] [Abstract][Full Text] [Related]
14. Evidence for altered Wnt signaling in psoriatic skin.
Gudjonsson JE; Johnston A; Stoll SW; Riblett MB; Xing X; Kochkodan JJ; Ding J; Nair RP; Aphale A; Voorhees JJ; Elder JT
J Invest Dermatol; 2010 Jul; 130(7):1849-59. PubMed ID: 20376066
[TBL] [Abstract][Full Text] [Related]
15. Loss of WIF-1 and Wnt5a expression is related to aggressiveness of sporadic breast cancer in Tunisian patients.
Trifa F; Karray-Chouayekh S; Jmal E; Jmaa ZB; Khabir A; Sellami-Boudawara T; Frikha M; Daoud J; Mokdad-Gargouri R
Tumour Biol; 2013 Jun; 34(3):1625-33. PubMed ID: 23417837
[TBL] [Abstract][Full Text] [Related]
16. Secreted Frizzled-related protein-1 is a negative regulator of androgen receptor activity in prostate cancer.
Kawano Y; Diez S; Uysal-Onganer P; Darrington RS; Waxman J; Kypta RM
Br J Cancer; 2009 Apr; 100(7):1165-74. PubMed ID: 19277043
[TBL] [Abstract][Full Text] [Related]
17. WNT5A induces release of exosomes containing pro-angiogenic and immunosuppressive factors from malignant melanoma cells.
Ekström EJ; Bergenfelz C; von Bülow V; Serifler F; Carlemalm E; Jönsson G; Andersson T; Leandersson K
Mol Cancer; 2014 Apr; 13():88. PubMed ID: 24766647
[TBL] [Abstract][Full Text] [Related]
18. WNT5A induces osteogenic differentiation of human adipose stem cells via rho-associated kinase ROCK.
Santos A; Bakker AD; de Blieck-Hogervorst JM; Klein-Nulend J
Cytotherapy; 2010 Nov; 12(7):924-32. PubMed ID: 20429785
[TBL] [Abstract][Full Text] [Related]
19. MiR-26a inhibits prostate cancer progression by repression of Wnt5a.
Zhao S; Ye X; Xiao L; Lian X; Feng Y; Li F; Li L
Tumour Biol; 2014 Oct; 35(10):9725-33. PubMed ID: 24972966
[TBL] [Abstract][Full Text] [Related]
20. WIF1 re-expression in glioblastoma inhibits migration through attenuation of non-canonical WNT signaling by downregulating the lncRNA MALAT1.
Vassallo I; Zinn P; Lai M; Rajakannu P; Hamou MF; Hegi ME
Oncogene; 2016 Jan; 35(1):12-21. PubMed ID: 25772239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
